Evidence map›Paper›PMID 32004074›Full record

ArticleAmerican journal of physiology. Heart and circulatory physiology2020

Antithrombotic effects of heme-degrading and heme-binding proteins.

Karl A Nath, Joseph P Grande, John D Belcher, Vesna D Garovic, Anthony J Croatt, Matthew L Hillestad, Michael A Barry, Meryl C Nath, Raymond F Regan, Gregory M Vercellotti

Open access · bronzeAbstract read
In one paragraph

Article in American journal of physiology. Heart and circulatory physiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Proteomics of arterial thrombi in acute limb ischemia.Journal of thrombosis and thrombolysis · 2025
    Article
  3. Review
  4. Review
  5. Review
  6. The spike protein of SARS-CoV-2 induces heme oxygenase-1: Pathophysiologic implications.Biochimica et biophysica acta. Molecular basis of disease · 2022
    Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Karl A NathDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota.
Joseph P GrandeDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
John D BelcherDivision of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota.
Vesna D GarovicDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota.
Anthony J CroattDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota.
Matthew L HillestadDivision of Infectious Diseases, Mayo Clinic, Rochester, Minnesota.
Michael A BarryDivision of Infectious Diseases, Mayo Clinic, Rochester, Minnesota.
Meryl C NathDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
Raymond F ReganDepartment of Emergency Medicine, University of Maryland School of Medicine, Baltimore, Maryland.
Gregory M VercellottiDivision of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota.
Mayo Clinic · USUniversity of Minnesota · USUniversity of Maryland, Baltimore · US

Funding

Hypertensive pregnancy disorders and future coronary artery diseaseR01HL136348 · NHLBI · MAYO CLINIC ROCHESTER · PI GAROVIC, VESNA D · 2018 to 2022
$2.6M
RENAL INJURY AND ADAPTATION TO HEME PROTEINSR01DK047060 · NIDDK · UNIVERSITY OF MINNESOTA TWIN CITIES · PI NATH, KARL A. · 1993 to 2018
$2.2M
The Murine Dialysis Fistula Model Exhibits a Senescence Phenotype: Pathobiologic Mechanisms and Therapeutic PotentialR01DK119167 · NIDDK · MAYO CLINIC ROCHESTER · PI NATH, KARL A. · 2019 to 2022
$1.7M
Protective Effect of Astrocyte Heme Oxygenase-1 after Intracerebral HemorrhageR01NS095205 · NINDS · UNIVERSITY OF MARYLAND BALTIMORE · PI REGAN, RAYMOND F · 2016 to 2020
$1.7M
NHLBI NIH HHS R01 HL136348NIDDK NIH HHS R01 DK047060NIDDK NIH HHS R01 DK119167NINDS NIH HHS R01 NS095205
6 · The paper itself

Abstract

In the murine venous thrombosis model induced by ligation of the inferior vena cava (IVCL), genetic deficiency of heme oxygenase-1 (HO-1) increases clot size. This study examined whether induction of HO-1 or administration of its products reduces thrombosis. Venous HO-1 upregulation by gene delivery reduced clot size, as did products of HO activity, biliverdin, and carbon monoxide. Induction of HO-1 by hemin reduced clot formation, clot size, and upregulation of plasminogen activator inhibitor-1 (PAI-1) that occurs in the IVCL model, while leaving urokinase plasminogen activator (uPA) and tissue plasminogen activator (tPA) expression unaltered. The reductive effect of hemin on clot size required HO activity. The IVCL model exhibited relatively high concentrations of heme that peaked just before maximum clot size, then declined as clot size decreased. Administration of hemin decreased heme concentration in the IVCL model. HO-2 mRNA was induced twofold in the IVCL model (vs. 40-fold HO-1 induction), but clot size was not increased in HO-2

Indexed as

Up-RegulationAnimalsDisease Models, AnimalHeme-Binding ProteinsHeme Oxygenase-1HeminMiceMice, KnockoutVenous ThrombosisHeme-Binding ProteinsHeme Oxygenase-1Heminbile pigmentscarbon monoxideheme oxygenase-1hemopexinmurine modelvenous thromboembolic disease

Identifiers

PMID32004074
PMCPMC7099452
OpenAlexW3004072344

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.